Company Overview of Jennerex Biotherapeutics, Inc.
Jennerex Biotherapeutics, Inc. develops oncolytic products for cancer. Its pipeline includes JX-594 for treating patients with liver and colorectal cancer; JX-929 for treating patients with pancreatic cancer; JX-1395 for treating patients with prostate cancer; and JX-next generation therapeutic classes for treating patients with various other cancers. The company’s products are designed to attack cancer tumors through synergistic and complementary mechanisms of action, such as lysis of cancer cells through viral replication, reduction of the blood supply to tumors through vascular targeting and destruction, and stimulation of the body's immune response against cancer cells. Jennerex Biothera...
450 Sansome Street
San Francisco, CA 94111
Founded in 2003
Key Executives for Jennerex Biotherapeutics, Inc.
Chief Executive Officer, President, and Director
Executive Vice President of Corporate Strategy
Head of Pusan Research Site and Research Advisor
Corporate Counsel and Director
Compensation as of Fiscal Year 2015.
Jennerex Biotherapeutics, Inc. Key Developments
Jennerex Biotherapeutics, Inc. Presents at BIO International Convention, Jun-23-2014
Jun 17 14
Jennerex Biotherapeutics, Inc. Presents at BIO International Convention, Jun-23-2014 . Venue: San Diego Convention Center, San Diego, California, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries